Sponsored Content Release
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.co
FinancialBuzz.com’s latest
The Buzz Show: Featuring Our Corporate News Recap on “Isoray Inc. Surges Upon FDA Clearance of its Sirius® Positive-Signal”
Isoray Inc. (NYSE: ISR) shot up over 227% in premarket trading after C4 Imaging announced its receipt of an FDA clearance.
C4 Imaging announced FDA clearance for the use of its Sirius® positive-signal MRI Markers with Isoray’s Cesium-131, brachytherapy seeds.
Isoray, Inc., through its subsidiary, Isoray Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com.
The
Buzz Show: Featuring Our Corporate News Recap on “Hoth Therapeutics Skyrockets Amid Production of its HT-001 for Cancer Treatment”
Hoth Therapeutics (NASDAQ: HOTH) shot up over 81% in premarket trading after announcing the production of its novel HT-001 for Cancer Treatment
The topical cancer treatment drug, HT-001, is designed for patients with mild to moderate rash and skin disorders associated with EGFR inhibitor therapy and is targeted to allow patients to achieve the best potential outcomes of EGFR therapy.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or
Sponsored Content Release
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.Finan